HC Wainwright Increases Spero Therapeutics (NASDAQ:SPRO) Price Target to $6.00

Key Points

• HC Wainwright raised Spero Therapeutics’ price target to $6.00 from $5.00 and maintained a “Buy” rating, implying approximately 431% upside from the prior close.
• Analyst sentiment remains mixed: Weiss Ratings upgraded the stock from “Sell” to “Hold,” while the broader analyst consensus is “Hold” with an average target price of $6.00.
• Spero shares opened at $1.13, near their 12-month low of $1.08. The company recently reported a quarterly loss of $0.16 per share, narrowly beating estimates, while institutional investors own 25.6% of its stock.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) had its price objective upped by research analysts at HC Wainwright from $5.00 to $6.00 in a research note issued to investors on Monday, Marketbeat.com reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 430.97% from the company's previous close.

Separately, Weiss Ratings raised Spero Therapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Spero Therapeutics has an average rating of "Hold" and an average target price of $6.00.

Spero Therapeutics Stock Performance

Shares of SPRO stock opened at $1.13 on Monday. The stock's 50 day simple moving average is $1.36 and its 200 day simple moving average is $2.12. Spero Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.08. The company has a market capitalization of $65.81 million, a price-to-earnings ratio of 10.27 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%.

Hedge Funds Weigh In On Spero Therapeutics

Several large investors have recently added to or reduced their stakes in SPRO. GSK plc acquired a new position in shares of Spero Therapeutics in the fourth quarter valued at $21,414,000. Alphabet Inc. bought a new stake in Spero Therapeutics in the 2nd quarter valued at $1,967,000. BlackRock Inc. acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $1,314,000. GSA Capital Partners LLP bought a new position in shares of Spero Therapeutics during the 2nd quarter worth about $632,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Spero Therapeutics during the 3rd quarter valued at about $283,000. Institutional investors and hedge funds own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.